BioSyent lance Inofolic® pour les femmes atteintes du syndrome des ovaires polykystiques (SOPK)
August 08, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 08 août 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) a le plaisir d’annoncer que sa filiale, BioSyent Pharma Inc., a...
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
August 08, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first...
BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
July 06, 2023 17:53 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, July 06, 2023 (GLOBE NEWSWIRE) -- BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the...
BioSyent Announces Long-term Extension of Cathejell® Agreement
June 20, 2023 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent Announces Approval of New Product
May 31, 2023 17:42 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received...
BioSyent Releases Financial Results for Q1 2023
May 26, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights...
BioSyent Declares Second Quarter 2023 Dividend
May 25, 2023 17:40 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023
May 18, 2023 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2023 on...
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!
May 02, 2023 14:59 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 02, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based...
FeraMAXᴹᴰ est le 1er choix de supplément de fer recommandé par les pharmaciens et les médecins canadiens, pour la huitième année consécutive!
May 02, 2023 14:59 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 02 mai 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que FeraMAXMD est le 1er choix de marque de supplément de...